The FDA has approved Eloxx Pharmaceuticals' Investigational New Drug application for exaluren to treat nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD). This clearance allows Eloxx to start its global Phase 2 EXPRESS trial in the U.S., enrolling about 60 patients to test exaluren against placebo over 52 weeks, focusing on kidney volume changes. Results are expected by the first half of 2029. The FDA indicated that significant effects on kidney volume could lead to Breakthrough Therapy Designation and accelerated approval, highlighting exaluren's potential as a novel treatment for this genetic kidney condition with no current targeted therapy.
Eloxx Pharmaceuticals' FDA clearance for exaluren provides context for health-sector stocks. For readers following health stocks, 95 of 150 US health-sector stocks rose and 47 fell on Pluang as of Oct 29, 2026 18:11 WIB. Notable movers include IOVA at USD 13.40 with a 9.52% drop and 100% sell order activity, BFLY at USD 8.25 up 5.63%, and THC at USD 254.80 down 5.10%.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
